Developer docs
API playgroundTry for free, no card

Search company profiles

Analgesic Solutions

Full company profile

uuid000y3wc

Namestring
Analgesic Solutions
Legal namestring
Analgesic Solutions
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Analgesic Solutions is a privately held clinical research services firm founded in 2006 and headquartered in Wayland, Massachusetts. Operating as a subsidiary brand under WCG Clinical, the company specializes in clinical trial endpoint assessment and trial optimization services for pharmaceutical sponsors and contract research organizations (CROs). It serves customers across eight therapeutic areas, including CNS/pain, cardiovascular, metabolic, hematology/oncology, infectious disease, dermatology, immunology, and gastroenterology. The company addresses well-documented pain points in clinical trials: high placebo response rates, inconsistent patient symptom reporting, and limited real-time visibility into blinded trial performance.

The company's product portfolio comprises four integrated offerings: (1) Placebo Response Reduction Training, a psychoeducational program that trains monitors, staff, and subjects to maintain neutral expectations and reduce measurement error; (2) Accurate Symptom Reporting, a patient training program built from the company's heritage in pain measurement that reduces variability and improves assay sensitivity; (3) Study Insight Analytics, a real-time monitoring platform that identifies statistically significant aberrant signals during blinded trials; and (4) an eCOA/ePRO platform for electronic clinical outcome and patient-reported outcome data collection. Together, these offerings target measurable improvements in trial data quality, endpoint accuracy, and trial efficiency.

Analgesic Solutions operates on a sales-led, consultative go-to-market motion with quote-based pricing. Revenue is generated through professional services engagements, software platform licensing for the eCOA/ePRO and Study Insight Analytics products, and training program fees. The company's digital presence has been consolidated into the parent WCG Clinical website (wcgclinical.com), giving it access to WCG's enterprise sales force, content marketing infrastructure, and industry events such as the MAGI@home 2026 conference. Distribution is global through direct enterprise sales engagement with pharmaceutical sponsors and CROs.

Short descriptiontext

Analgesic Solutions, a subsidiary brand of WCG Clinical, provides clinical trial endpoint optimization services for pharmaceutical sponsors and CROs, including placebo response reduction training, symptom reporting programs, real-time trial analytics, and eCOA/ePRO platforms across eight therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWayland, United States
HQ citystring
Wayland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial consulting, placebo response reduction, endpoint assessment training, eCOA ePRO platform, clinical trial analytics
Industry1 code
PRIMARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code1 code
  • Custom Computer Programming Services541511
SIC code3 codes
  • Services-Management Consulting Services8742
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Health Services8000
Product category
Clinical Trial Endpoint Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Solutions Services
TypeSubscription Recurring
Description

Provides specialized clinical trial endpoint assessment and optimization services to pharmaceutical sponsors and CROs. Revenue is generated through professional services engagements, software platform licensing (eCOA/ePRO, Study Insight Analytics), and training programs.

wcgclinical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Analgesic Solutions provides specialized clinical trial endpoint assessment and optimization services to pharmaceutical sponsors and CROs. Its offerings include placebo response reduction training, accurate symptom reporting programs, real-time study insight analytics, and an eCOA/ePRO platform designed to improve data quality, reduce measurement error, and enhance assay sensitivity in clinical trials. The company operates as a WCG Clinical brand focused on the analgesic and pain therapy therapeutic area.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces measurement error and improves assay sensitivity through placebo response reduction training
+1 more record
Product overview1 text field

Analgesic Solutions offers a suite of clinical trial solutions focused on endpoint assessment and pain measurement. As part of WCG Clinical's integrated platform, the core offerings include Placebo Response Reduction Training, Accurate Symptom Reporting, Study Insight Analytics, and the eCOA/ePRO Platform. These solutions work together to reduce placebo response, improve data quality, and enhance assay sensitivity in clinical trials. The company operates as a WCG Clinical brand, consolidated into wcgclinical.com alongside WCG's broader portfolio of clinical research solutions including IRB review, site enablement, and data management tools.

Product and service1 record
1Placebo Response Reduction Training
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medidata, a Dassault Systèmes brand, is a broad incumbent in clinical trial technology including eCOA/ePRO (Medidata Patient Cloud), RTSM, and analytics. It overlaps with Analgesic Solutions' technology stack but operates at much larger scale across all trial phases and therapeutic areas.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO and offers broad clinical trial services including eCOA, real-world evidence, and endpoint analytics. It competes with Analgesic Solutions across the CRO/sponsor customer base but at vastly greater scale and breadth.

TypeDirect peer
Description

YPrime provides eCOA, IRT, and clinical supply technologies with strong capabilities in pain and CNS trials. It directly competes with Analgesic Solutions' eCOA/ePRO offering and serves overlapping pharmaceutical sponsors.

TypeBroad incumbent
Description

ICON is a major global CRO offering full-service clinical development, including endpoint assessment and eCOA capabilities. It competes broadly with Analgesic Solutions for pharma sponsor budgets but at much larger enterprise scale.

TypeBroad incumbent
Description

Calyx provides eClinical solutions including IRT, EDC, and CTMS that are sometimes adjacent to endpoint assessment workflows. It overlaps with parts of Analgesic Solutions' clinical trial technology stack and serves similar sponsors.

TypeEmerging player
Description

Castor is an emerging clinical trial technology platform offering ePRO, eConsent, and decentralized trial capabilities. It competes at the technology layer with Analgesic Solutions' eCOA/ePRO offering, particularly for smaller and mid-sized sponsors.

TypeDirect peer
Description

MedAvante-ProPhase, now a sister brand under WCG Clinical alongside Analgesic Solutions, provides centralized ratings and clinical outcome assessment services for CNS trials. The two units share the same parent and overlapping customer base in endpoint assessment for CNS/pain.

TypeDirect peer
Description

Clinical Ink provides eCOA, ePRO, and direct data capture solutions for clinical trials, particularly in CNS and rare disease. It directly competes with Analgesic Solutions' eCOA/ePRO platform for endpoint assessment business.

TypeDirect peer
Description

Signant Health provides eCOA, ePRO, patient engagement, and clinical supply technology for clinical trials. It directly competes with Analgesic Solutions' eCOA/ePRO and Study Insight Analytics offerings in CNS and pain trials.

TypeDirect peer
Description

Clario is a leading provider of clinical endpoint technology, eCOA/ePRO, cardiac safety, and imaging solutions for clinical trials. It directly overlaps with Analgesic Solutions' eCOA/ePRO platform and endpoint assessment offerings, and serves the same pharmaceutical sponsor and CRO customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Analgesic Solutions

Clinical Trial Endpoint Servicesanalgesicsolutions.com

Analgesic Solutions, a subsidiary brand of WCG Clinical, provides clinical trial endpoint optimization services for pharmaceutical sponsors and CROs, including placebo response reduction training, symptom reporting programs, real-time trial analytics, and eCOA/ePRO platforms across eight therapeutic areas.

What Analgesic Solutions does

Analgesic Solutions is a privately held clinical research services firm founded in 2006 and headquartered in Wayland, Massachusetts. Operating as a subsidiary brand under WCG Clinical, the company specializes in clinical trial endpoint assessment and trial optimization services for pharmaceutical sponsors and contract research organizations (CROs). It serves customers across eight therapeutic areas, including CNS/pain, cardiovascular, metabolic, hematology/oncology, infectious disease, dermatology, immunology, and gastroenterology. The company addresses well-documented pain points in clinical trials: high placebo response rates, inconsistent patient symptom reporting, and limited real-time visibility into blinded trial performance.

The company's product portfolio comprises four integrated offerings: (1) Placebo Response Reduction Training, a psychoeducational program that trains monitors, staff, and subjects to maintain neutral expectations and reduce measurement error; (2) Accurate Symptom Reporting, a patient training program built from the company's heritage in pain measurement that reduces variability and improves assay sensitivity; (3) Study Insight Analytics, a real-time monitoring platform that identifies statistically significant aberrant signals during blinded trials; and (4) an eCOA/ePRO platform for electronic clinical outcome and patient-reported outcome data collection. Together, these offerings target measurable improvements in trial data quality, endpoint accuracy, and trial efficiency.

Analgesic Solutions operates on a sales-led, consultative go-to-market motion with quote-based pricing. Revenue is generated through professional services engagements, software platform licensing for the eCOA/ePRO and Study Insight Analytics products, and training program fees. The company's digital presence has been consolidated into the parent WCG Clinical website (wcgclinical.com), giving it access to WCG's enterprise sales force, content marketing infrastructure, and industry events such as the MAGI@home 2026 conference. Distribution is global through direct enterprise sales engagement with pharmaceutical sponsors and CROs.

Analgesic Solutions firmographics

Firmographics
Name
Analgesic Solutions
Legal name
Analgesic Solutions
Website
https://analgesicsolutions.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Analgesic Solutions, a subsidiary brand of WCG Clinical, provides clinical trial endpoint optimization services for pharmaceutical sponsors and CROs, including placebo response reduction training, symptom reporting programs, real-time trial analytics, and eCOA/ePRO platforms across eight therapeutic areas.
Ownership category
akta.pro rank

Analgesic Solutions industry classification

Industry
Product category
Clinical Trial Endpoint Services
NAICS
Custom Computer Programming Services (541511)
SIC
Services-Management Consulting Services (8742), Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Clinical trial consulting
  • Placebo response reduction
  • Endpoint assessment training
  • ECOA ePRO platform
  • Clinical trial analytics

Where Analgesic Solutions is headquartered

Location

Headquarters

HQ city
Wayland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Analgesic Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Clinical Trial Solutions Services: Provides specialized clinical trial endpoint assessment and optimization services to pharmaceutical sponsors and CROs. Revenue is generated through professional services engagements, software platform licensing (eCOA/ePRO, Study Insight Analytics), and training programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Analgesic Solutions product offering

Product offering

Core offering

Analgesic Solutions provides specialized clinical trial endpoint assessment and optimization services to pharmaceutical sponsors and CROs. Its offerings include placebo response reduction training, accurate symptom reporting programs, real-time study insight analytics, and an eCOA/ePRO platform designed to improve data quality, reduce measurement error, and enhance assay sensitivity in clinical trials. The company operates as a WCG Clinical brand focused on the analgesic and pain therapy therapeutic area.

Product overview

Analgesic Solutions offers a suite of clinical trial solutions focused on endpoint assessment and pain measurement. As part of WCG Clinical's integrated platform, the core offerings include Placebo Response Reduction Training, Accurate Symptom Reporting, Study Insight Analytics, and the eCOA/ePRO Platform. These solutions work together to reduce placebo response, improve data quality, and enhance assay sensitivity in clinical trials. The company operates as a WCG Clinical brand, consolidated into wcgclinical.com alongside WCG's broader portfolio of clinical research solutions including IRB review, site enablement, and data management tools.

Differentiator

Problem solved

Functional benefit

Products and services

  • Placebo Response Reduction Training

Quantifiable outcome

  • Reduces measurement error and improves assay sensitivity through placebo response reduction training
  • +1 more outcomes

Companies that use Analgesic Solutions

Customer profile

Segments3 records

Ideal customer profiles2 records

Analgesic Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Analgesic Solutions partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Analgesic Solutions competitors and assessment

Company assessment

Broad incumbents

  • Medidata Solutions (Dassault Systèmes): Medidata, a Dassault Systèmes brand, is a broad incumbent in clinical trial technology including eCOA/ePRO (Medidata Patient Cloud), RTSM, and analytics. It overlaps with Analgesic Solutions' technology stack but operates at much larger scale across all trial phases and therapeutic areas.
  • IQVIA: IQVIA is the world's largest CRO and offers broad clinical trial services including eCOA, real-world evidence, and endpoint analytics. It competes with Analgesic Solutions across the CRO/sponsor customer base but at vastly greater scale and breadth.
  • ICON plc: ICON is a major global CRO offering full-service clinical development, including endpoint assessment and eCOA capabilities. It competes broadly with Analgesic Solutions for pharma sponsor budgets but at much larger enterprise scale.
  • Calyx (formerly Parexel informatics): Calyx provides eClinical solutions including IRT, EDC, and CTMS that are sometimes adjacent to endpoint assessment workflows. It overlaps with parts of Analgesic Solutions' clinical trial technology stack and serves similar sponsors.

Direct peers

  • YPrime: YPrime provides eCOA, IRT, and clinical supply technologies with strong capabilities in pain and CNS trials. It directly competes with Analgesic Solutions' eCOA/ePRO offering and serves overlapping pharmaceutical sponsors.
  • MedAvante-ProPhase (now part of WCG): MedAvante-ProPhase, now a sister brand under WCG Clinical alongside Analgesic Solutions, provides centralized ratings and clinical outcome assessment services for CNS trials. The two units share the same parent and overlapping customer base in endpoint assessment for CNS/pain.
  • Clinical Ink: Clinical Ink provides eCOA, ePRO, and direct data capture solutions for clinical trials, particularly in CNS and rare disease. It directly competes with Analgesic Solutions' eCOA/ePRO platform for endpoint assessment business.
  • Signant Health (formerly Bracket): Signant Health provides eCOA, ePRO, patient engagement, and clinical supply technology for clinical trials. It directly competes with Analgesic Solutions' eCOA/ePRO and Study Insight Analytics offerings in CNS and pain trials.
  • Clario (formerly ERT / Bioclinica): Clario is a leading provider of clinical endpoint technology, eCOA/ePRO, cardiac safety, and imaging solutions for clinical trials. It directly overlaps with Analgesic Solutions' eCOA/ePRO platform and endpoint assessment offerings, and serves the same pharmaceutical sponsor and CRO customers.

Emerging players

  • Castor: Castor is an emerging clinical trial technology platform offering ePRO, eConsent, and decentralized trial capabilities. It competes at the technology layer with Analgesic Solutions' eCOA/ePRO offering, particularly for smaller and mid-sized sponsors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Analgesic Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Analgesic Solutions leadership team

Management profile

Number of profiles

Analgesic Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Analgesic Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Analgesic Solutions

What does Analgesic Solutions do?

Analgesic Solutions provides specialized clinical trial endpoint assessment and optimization services to pharmaceutical sponsors and CROs. Its offerings include placebo response reduction training, accurate symptom reporting programs, real-time study insight analytics, and an eCOA/ePRO platform designed to improve data quality, reduce measurement error, and enhance assay sensitivity in clinical trials. The company operates as a WCG Clinical brand focused on the analgesic and pain therapy therapeutic area.

Is Analgesic Solutions a public or private company?

Analgesic Solutions is a private company. It is classified as corporate owned and is currently operating.

When was Analgesic Solutions founded?

Analgesic Solutions was founded in 2006. It employs 11 to 50 people.

Where is Analgesic Solutions based?

Analgesic Solutions is headquartered in Wayland, United States, in the North America region.

How does Analgesic Solutions make money?

One revenue line is on record: clinical Trial Solutions Services.

Who are Analgesic Solutions's main competitors?

Broad incumbents on record are Medidata Solutions (Dassault Systèmes), IQVIA, ICON plc and Calyx (formerly Parexel informatics). Direct peers are YPrime, MedAvante-ProPhase (now part of WCG), Clinical Ink, Signant Health (formerly Bracket) and Clario (formerly ERT / Bioclinica). Castor is listed as an emerging player.

Does Analgesic Solutions have an API?

No public API is recorded for Analgesic Solutions.

What industry is Analgesic Solutions in?

Analgesic Solutions's product category is Clinical Trial Endpoint Services. Its primary akta.pro industry code is HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 541511 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWCG Announces the Acquisition of Analgesic Solutions, LLCWCG announced the acquisition of Analgesic Solutions, a provider of pain-management clinical trial solutions. The deal adds Analgesic Solutions' expertise in improving assay sensitivity and reducing measurement error to WCG's clinical services. Analgesic Solutions will continue operating independently from its Wayland, MA headquarters.PR NewswireAnalgesic Solutions Presenting MADDERS® System at the Human Abuse Liability Testing and Market Access MeetingAnalgesic Solutions announced that Dr. Ryan Lanier will present at the 5th Annual Human Abuse Liability Testing & Market Access Conference in Herndon, VA on November 6, 2018, discussing the company's MADDERS (Misuse, Abuse, and Diversion Drug Event Reporting System) platform. The MADDERS system is described as the only standardized, prospective method for meeting FDA regulatory requirements to assess abuse potential of drugs in clinical trials, having been successfully implemented in multiple Phase 2-4 trials of CNS-active compounds.PR NewswireAnalgesic Solutions Presenting MADDERS® System at the Advancements and Challenges in Abuse Potential Evaluation MeetingDr. Ryan Lanier from Analgesic Solutions will present the company's MADDERS® system for monitoring drug misuse, abuse, and diversion in clinical trials at the Advancements and Challenges in Abuse Potential Evaluation Meeting on October 11, 2018 in Bethesda, MD. The system was developed based on recommendations from ACTTION, a public-private partnership with the FDA, and fulfills the 2017 FDA requirement for comprehensive abuse potential assessment of investigational Central Nervous System-active drug products. The meeting is organized by the Cross-Company Abuse Liability Council (CCALC) with support from the FDA and the National Institute on Drug Abuse (NIDA).PR NewswireAnalgesic Solutions Announces New Executive Management TeamAnalgesic Solutions announced a restructuring of its executive leadership, promoting Robert Newman to CEO and appointing new heads for operations and technology roles. The company stated that these changes are intended to drive continued growth and expand into data-driven application areas beyond the pain management sector.PR NewswireJacqueline Delfgaauw, Ph.D. joins Analgesic Solutions as Executive Director, Clinical ScienceAnalgesic Solutions LLC announced the appointment of Jacqueline Delfgaauw, Ph.D. as Executive Director, Clinical Science. Dr. Delfgaauw brings over 15 years of experience focused exclusively on clinical development of analgesics, including senior roles at Grunenthal where she led clinical development for Latin America, the U.S., and Canada. She will serve as a key member of the senior management team leading clinical development efforts, particularly the company's Quantitative Data Surveillance System (QDSS) platform.PR NewswireAnalgesic Solutions Presents Data on the use of MADDERS® to Assess Potentially Abuse-Related Events in Clinical Trials at the 79th Annual Scientific Meeting of The College on Problems of Drug DependenAnalgesic Solutions presented MADDERS data at the CPDD meeting in Montreal, with CEO Nathaniel Katz leading a workshop on abuse-related event assessment. The system has been implemented in at least nine Phase III trials and one Phase IV trial. Two posters on Phase III trials of Epidiolex and Sativex were also presented.PR NewswireAnalgesic Solutions Announces Presentation of Signature Quantitative Data Surveillance SystemAnalgesic Solutions announced the presentation of its Quantitative Data Surveillance System (QDSS) at the International Association for the Study of Pain symposium in Yokohama, Japan. QDSS is a central statistical surveillance tool designed for prospective monitoring of assay sensitivity in multicenter clinical trials, utilizing statistical process control methods to detect factors impacting clinical signals. The system has been deployed in five international multicenter clinical trials involving over 7,000 subjects across 350 sites in 22 countries.PR NewswireArturo Morales, Ph.D., Joins Analgesic Solutions as Chief Technology OfficerAnalgesic Solutions, a specialty consulting and clinical research company based in Natick, Massachusetts, announced the appointment of Arturo Morales, Ph.D. as Chief Technology Officer. Dr. Morales brings over fifteen years of experience in data science, information technology, and computational biology from previous roles at Beryllium Discovery, Novartis Institutes for Biomedical Research, and other organizations. He will oversee the company's technical operations including the development and commercialization of Analgesic Solutions' proprietary Quantitative Data Surveillance System (QDSS) platform.